Takahisa Kawamura1,2, Chiyo K Imamura1, Hirotsugu Kenmotsu1,2, Tetsuhiko Taira3, Shota Omori2, Kazuhisa Nakashima2, Kazushige Wakuda2, Akira Ono2, Tateaki Naito2, Haruyasu Murakami2, Taisei Mushiroda4, Toshiaki Takahashi2, Yusuke Tanigawara5. 1. Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. 2. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan. 3. Division of Medical Oncology, Sagara Hospital, 3-31 Matsubara-cho, Kagoshima City, Kagoshima, 892-0833, Japan. 4. Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Japan. 5. Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. tanigawara-yusuke@umin.ac.jp.
Abstract
PURPOSE: Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dose gefitinib in patients with experience of severe hepatotoxicity might be higher than that in patients without severe hepatotoxicity. METHODS: Patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer who were receiving gefitinib either at a reduced dose (250 mg every other day) because of intolerable severe toxicity or at a standard dose (250 mg daily) were enrolled. A series of blood samples were collected to estimate pharmacokinetic parameters and calculate systemic exposure of standard-dose gefitinib (area under the concentration-time curve from 0 to 24 h at steady state, AUC0-24,ss). Systemic exposure of unbound gefitinib (fu·AUC0-24,ss) was also assessed, because gefitinib is extensively bound to serum proteins. RESULTS: Of the 38 enrolled patients, 34 (23 patients without experience of severe hepatotoxicity, 11 patients with experience of severe hepatotoxicity) were evaluable. There was no significant differences in total AUC0-24,ss or unbound fu·AUC0-24,ss between patients with and without experience of severe hepatotoxicity. Analysis of the time to severe hepatotoxicity indicated no difference between patients with a high AUC0-24,ss and those with a low AUC0-24,ss of either total or unbound gefitinib. CONCLUSION: This study suggests that reversible severe hepatotoxicity is not caused by high systemic exposure of gefitinib.
PURPOSE: Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dose gefitinib in patients with experience of severe hepatotoxicity might be higher than that in patients without severe hepatotoxicity. METHODS:Patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer who were receiving gefitinib either at a reduced dose (250 mg every other day) because of intolerable severe toxicity or at a standard dose (250 mg daily) were enrolled. A series of blood samples were collected to estimate pharmacokinetic parameters and calculate systemic exposure of standard-dose gefitinib (area under the concentration-time curve from 0 to 24 h at steady state, AUC0-24,ss). Systemic exposure of unbound gefitinib (fu·AUC0-24,ss) was also assessed, because gefitinib is extensively bound to serum proteins. RESULTS: Of the 38 enrolled patients, 34 (23 patients without experience of severe hepatotoxicity, 11 patients with experience of severe hepatotoxicity) were evaluable. There was no significant differences in total AUC0-24,ss or unbound fu·AUC0-24,ss between patients with and without experience of severe hepatotoxicity. Analysis of the time to severe hepatotoxicity indicated no difference between patients with a high AUC0-24,ss and those with a low AUC0-24,ss of either total or unbound gefitinib. CONCLUSION: This study suggests that reversible severe hepatotoxicity is not caused by high systemic exposure of gefitinib.
Entities:
Keywords:
Gefitinib; Non-small cell lung cancer; Pharmacokinetics; Protein binding; Severe hepatotoxicity; Systemic exposure
Authors: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steve Averbuch; Judy Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: K Nakagawa; T Tamura; S Negoro; S Kudoh; N Yamamoto; N Yamamoto; K Takeda; H Swaisland; I Nakatani; M Hirose; R-P Dong; M Fukuoka Journal: Ann Oncol Date: 2003-06 Impact factor: 32.976
Authors: N Widmer; L A Decosterd; S Leyvraz; M A Duchosal; A Rosselet; M Debiec-Rychter; C Csajka; J Biollaz; T Buclin Journal: Br J Cancer Date: 2008-05-06 Impact factor: 7.640